TAMPA, Fla., Jan. 8 /PRNewswire/ -- Researchers at the H. Lee Moffitt Cancer Center & Research Institute have unlocked at least part of the mystery of how tumors flourish undetected by keeping their presence a secret from the sentries of the body’s immune system.
“Flying beneath the radar” is how Nature Reviews Cancer (http://www.nature.com/cgi- taf/DynaPage.taf?file=/nrc/journal/v4/n1/full/nrc1261_fs.html) labels the mechanism of tumors evading capture, a process described by Hua Yu, Ph.D., and her colleagues in the current issue of the journal Nature Medicine.
“Cancer is allowed to wreak havoc on the body’s immune system because it knows how to fool the body’s defensive arsenal,” explains Jack Pledger, Ph.D., Associate Center Director for Basic Science. “The discoveries of Dr. Yu give us vital information about how tumors stay ‘invisible.’ It opens the way for new treatments to help flush the cancer cells into the open, so the body’s armies against disease can destroy them.”
Yu is an Associate Professor in the Immunology Program at Moffitt. Her coauthors on the study include Drew Pardoll, M.D., Ph.D., from the Johns Hopkins University School of Medicine, together with Richard Jove, Ph.D., and William Dalton, Ph.D., M.D., both from Moffitt. The study is titled “Regulation of the innate and adaptive immune responses by Stat3 signaling in tumor cells.”
The researchers documented that the tumor’s activation of Stat3 (from the STAT family of proteins that regulates genes) secretes factors that inhibit the body’s immune responses by keeping dendritic cells from maturing. The activation also blocks expression of inflammatory mediators required to trigger the immune system.
Other ongoing research at Moffitt related to Stat3 includes using microarray technology to study the characteristic gene expression profiles or “molecular signatures” of certain genes that are regulated by the STAT. Scientists suspect that many genes that are directly or indirectly regulated by Stat3 may contribute to cancer, and they are working to develop new drugs based on inhibiting Stat3 for more effective treatment of breast cancer, prostate cancer, sarcoma, melanoma and other tumors.
Moffitt is an NCI-designated Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.
H. Lee Moffitt Cancer Center
CONTACT: Andrea Brunais, H. Lee Moffitt Cancer Center, +1-813-632-1478,or MediaRelations@moffitt.usf.edu